EGFR and non-small cell lung carcinoma: Numerous clinical trials have shown the superior efficacy of first‐generation EGFR‐TKIs (gefitinib and erlotinib) or second‐generation EGFR‐TKIs (afatinib) compared with chemotherapy6, 7, 8, 9, 10, 11 and have established these agents as the standard of care for advanced EGFR‐mutated NSCLC.